Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Slavik

Showing results (101-110 of 134) with videos related to

Pageof 14
Sort By:
The Journal of Experimental Medicine|November 6, 2002
Reduced self-reactivity of an autoreactive T cell after activation with cross-reactive non-self-ligandMarkus Munder, Estelle Bettelli, Laurent Monney, et al.
Oncology|January 1, 1976
Neocarzinostatin (NSC 157365) a new cancerostatic compoundS S Legha, D D Von Hoff, M Rozencweig, et al.
Cancer Treatment Reports|January 1, 1987
Phase II trial of spirogermanium in central nervous system tumors: a Southwest Oncology Group StudyJ W Goodwin, J Crowley, B Tranum, et al.
Investigational New Drugs|January 1, 1985
Phase I evaluation of chlorozotocin (NSC-178248): weekly scheduleW J Moriconi, S Taylor, M Slavik, et al.
Neoplasma|March 4, 2017
Patterns of failure after brain metastases radiotherapy: reflections on the importance for treatment and clinical trials reportingR Lakomy, L Hynkova, P Pospisil, et al.
Investigational New Drugs|January 1, 1995
Evaluation of merbarone (NSC 336628) in disseminated malignant melanoma. A Southwest Oncology Group studyM Slavik, P Y Liu, E H Kraut, et al.
Cancer Treatment Reports|October 1, 1980
Phase I clinical trial of spirogermaniumP S Schein, M Slavik, T Smythe, et al.
American Journal of Veterinary Research|September 1, 1980
An age-related coagulation disorder associated with experimental infection with infectious bursal disease virusJ K Skeeles, M Slavik, J N Beasley, et al.
Immunological Reviews|March 26, 2005
Multiple sclerosisDavid A Hafler, Jacqueline M Slavik, David E Anderson, et al.
Rozhledy V Chirurgii : Mesicnik Ceskoslovenske Chirurgicke Spolecnosti|December 7, 2024
Perioperative systemic therapy as a part of comprehensive multimodal treatment in esophageal and gastric cancer - new treatment guidelinesR Lordick Obermannová, V Jedlička, J Dvorský, et al.
Pageof 14

Showing results (101-110 of 134) with videos related to

Sort By:
Pageof 14
The Journal of Experimental Medicine|November 6, 2002
Reduced self-reactivity of an autoreactive T cell after activation with cross-reactive non-self-ligandMarkus Munder, Estelle Bettelli, Laurent Monney, et al.
Oncology|January 1, 1976
Neocarzinostatin (NSC 157365) a new cancerostatic compoundS S Legha, D D Von Hoff, M Rozencweig, et al.
Cancer Treatment Reports|January 1, 1987
Phase II trial of spirogermanium in central nervous system tumors: a Southwest Oncology Group StudyJ W Goodwin, J Crowley, B Tranum, et al.
Investigational New Drugs|January 1, 1985
Phase I evaluation of chlorozotocin (NSC-178248): weekly scheduleW J Moriconi, S Taylor, M Slavik, et al.
Neoplasma|March 4, 2017
Patterns of failure after brain metastases radiotherapy: reflections on the importance for treatment and clinical trials reportingR Lakomy, L Hynkova, P Pospisil, et al.
Investigational New Drugs|January 1, 1995
Evaluation of merbarone (NSC 336628) in disseminated malignant melanoma. A Southwest Oncology Group studyM Slavik, P Y Liu, E H Kraut, et al.
Cancer Treatment Reports|October 1, 1980
Phase I clinical trial of spirogermaniumP S Schein, M Slavik, T Smythe, et al.
American Journal of Veterinary Research|September 1, 1980
An age-related coagulation disorder associated with experimental infection with infectious bursal disease virusJ K Skeeles, M Slavik, J N Beasley, et al.
Immunological Reviews|March 26, 2005
Multiple sclerosisDavid A Hafler, Jacqueline M Slavik, David E Anderson, et al.
Rozhledy V Chirurgii : Mesicnik Ceskoslovenske Chirurgicke Spolecnosti|December 7, 2024
Perioperative systemic therapy as a part of comprehensive multimodal treatment in esophageal and gastric cancer - new treatment guidelinesR Lordick Obermannová, V Jedlička, J Dvorský, et al.
Pageof 14